Jul 2026· Strabismus· pp.
1-10
· 0 citations· 30 references
Medicine
TL;DR
Vision therapy can produce clinically meaningful and durable visual improvements in amblyopic patients who no longer respond to occlusion alone, and supports extending amblyopia treatment into adolescence and adulthood, while emphasizing the need for tailored approaches based on the etiology of amblyopia and age.
Abstract
Purpose
To evaluate long‑term visual acuity (VA) trends following a structured vision therapy protocol in patients with amblyopia who had plateaued after conventional occlusion therapy.
Methods
This prospective cohort study included 157 patients diagnosed with amblyopia who showed no further VA improvement over at least three consecutive assessments during standard patching. All participants received individualized vision therapy comprising monocular and binocular exercises, fusion training, fixation stabilization, and perceptual tasks, combined with limited daily occlusion (1-3 hours). Therapy was delivered over 15 weekly in‑clinic sessions, followed by a structured home program. Visual acuity was monitored every 6 months over a 48‑month follow‑up period.
Results
A total of 177 amblyopic eyes from 157 patients (mean age 15.56 ± 10.6 years) were analyzed. Mean VA improved from 0.50 ± 0.23 at baseline to 0.70 ± 0.28 at 48 months (p < .001); 48.6% of eyes achieved a final VA of ≥0.8 decimal. Significant VA gains were observed across all age groups, with mean improvements of 0.24, 0.21, and 0.16 in decimal VA for ages ≤ 8 years, 8-18 years, and >18 years, respectively. The proportion of patients gaining ≥ 2 lines of VA was highest in the ≤8 years (62.5%) and 8-18 years (62.5%) groups, compared with 35.4% in those > 18 years. Isoametropic amblyopia showed the highest rate of ≥2‑line improvement (65.0%), followed by strabismic (63.6%) and anisometropic (44.2%) types. No statistically significant difference in visual outcomes was observed between the two protocols (Haidinger's brushes/flashing vs. adding perceptual learning; p = .385).
Conclusion
Vision therapy can produce clinically meaningful and durable visual improvements in amblyopic patients who no longer respond to occlusion alone. The present study also supports extending amblyopia treatment into adolescence and adulthood, while emphasizing the need for tailored approaches based on the etiology of amblyopia and age.
Administering vision therapy in conjunction with patching significantly improved VA, stereo acuity, and accommodation facility in bilateral refractive amblyopia compared to patching alone.
Saeedeh Hoseinmenni, S. Rahmani, Ebrahim Jafarzadehpour et al.· Journal of Ophthalmic & Visi...· 0 citations
Luminopia demonstrated significant improvements in Registry patients with severe amblyopia, particularly in treatment-naive patients, supporting its use as a viable treatment option that may address key limitations of traditional approaches.
Courtney L. Kraus, A. Godfrey, E. Gaier et al.· Journal of AAPOS· 1 citation
Active vision therapy leads to significant and accelerates improvements in CS among children with bilateral refractive amblyopia and demonstrates a rate of change in monocular CS of 0.05 during follow-up time.
Saeed Rahmani, Saeedeh Hoseinmenni, C. Dehghani et al.· International Journal of Oph...· 0 citations
AVT with occlusion was associated with greater improvements in functional visuomotor task performance and visual outcomes in children with anisometropic amblyopia, supporting its role as a function-oriented adjunct to conventional therapy.
Manisha Koirala, Sanjeev Bhattarai, J. Shrestha et al.· Journal of Optometry· 0 citations
Use of a dichoptic digital therapeutic device in the treatment and management of amblyopia holds exciting potential in deprivation amblyopia, although a percentage of patients with severe amblyopia did show modest improvement.
W. Sambhariya, Courtney L. Kraus· Journal of pediatric ophthal...· 0 citations
Overall, CureSight was noninferior to patching in these amblyopia types and yielded better visual outcomes in children completing ≥ 60% dosage, supporting binocular therapy as an additional first-line option.
O. Yehezkel, T. Wygnanski-Jaffe, B. Kushner et al.· Scientific Reports· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.